Brief: Merus' Petosemtamab Monotherapy Interim Data Continues To Demonstrate Clinically Meaningful Activity In 2L+ R/M HNSCC
07/12/2024 07:32
Dec 7 (Reuters) - Merus NV 2GH.F :
* MERUS' PETOSEMTAMAB MONOTHERAPY INTERIM DATA CONTINUES TO
DEMONSTRATE CLINICALLY MEANINGFUL ACTIVITY IN 2L+ R/M HNSCC
Source text: ID:nGNE2WGYys
Further company coverage: 2GH.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Merus NV
See all newsNASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Merus And Halozyme enter global collaboration and license agreement to develop subcutaneous formulation Of Petosemtamab